Organization Profile

You just read:

Health Canada has authorized VYVANSE® (lisdexamfetamine dimesylate), the first and only, chewable tablet for the treatment of attention deficit/hyperactivity disorder (ADHD)1*

News provided by

Takeda Canada

Jul 10, 2019, 07:00 ET